Details for New Drug Application (NDA): 012665
✉ Email this page to a colleague
NDA 012665 describes VELBAN, which is a drug marketed by Lilly and is included in one NDA. Additional details are available on the VELBAN profile page.
The generic ingredient in VELBAN is vinblastine sulfate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the vinblastine sulfate profile page.
The generic ingredient in VELBAN is vinblastine sulfate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the vinblastine sulfate profile page.
Summary for 012665
| Tradename: | VELBAN |
| Applicant: | Lilly |
| Ingredient: | vinblastine sulfate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 012665
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
